arrow
L

Lawrence J. Druhan

University System of Ohio
H指数:31
被引数:3,698

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas

通过抑制Aurora激酶上调TP53,克服了BCL2重排淋巴瘤对Venetoclax的原发耐药。

2025-06-010
OAAI
Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

具有不确定潜力的克隆性造血与接受嵌合抗原受体T细胞疗法治疗的多发性骨髓瘤和非霍奇金淋巴瘤患者中炎症毒性的降低和晚期血细胞减少的增加相关。

BLOOD
IF23.1
2024-11-050
PRE